Lidocaine Accord

Lidocaine, the active ingredient in Lidocaine Accord, is a local anesthetic presented as a sterile solution for epidural, intramuscular, and intravenous use. It provides reversible loss of sensation for minor surgical procedures and regional anesthesia. GNH USA supplies Lidocaine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lidocaine Accord is a local anesthetic used in procedures requiring nerve impulse blockade. - Minor surgical procedures: provides reversible loss of sensation at the targeted site. - Epidural analgesia: delivers effective pain relief during labor or postoperative periods. - Regional anesthesia (intramuscular or intravenous): facilitates nerve block for limb surgeries.

Adverse reactions may occur following administration of lidocaine.

Common Side Effects: - Tingling or numbness at the injection site - Mild dizziness or light‑headedness - Transient hypotension - Nausea or vomiting - Metallic taste in the mouth - Localised swelling or erythema

Serious or Rare Side Effects: - Cardiac arrhythmias, including ventricular tachycardia - Seizures or convulsions - Methemoglobinemia leading to cyanosis - Severe allergic reactions such as anaphylaxis - Respiratory depression - Persistent neurological deficits

Lidocaine should be used with careful assessment of patient‑specific risk factors. - Allergy assessment: confirm no known hypersensitivity to amide‑type local anesthetics. - Cardiovascular monitoring: observe for arrhythmias in patients with heart disease. - Dose limitation: avoid exceeding the recommended total dose for the selected route. - Concurrent CNS depressants: use with caution when combined with other central nervous system depressants. - Pregnancy and lactation: evaluate risk‑benefit ratio before use. - Store at below 25°C: keep in the original container, protect from light and moisture.

Lidocaine may interact with other medicines, altering its safety profile.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may potentiate cardiotoxicity. - Beta‑blockers: increase risk of bradycardia and hypotension. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma lidocaine levels.

Moderate Interactions (Monitor Closely): - General anesthetics (e.g., propofol): additive central nervous system depression. - Opioids: enhanced respiratory depression. - Diuretics: may affect plasma concentration and clearance.